CureVac begins Phase I Omicron-targeting Covid-19 vaccine trial

CureVac has initiated the Phase I clinical trial of the modified Covid-19 messenger ribonucleic acid (mRNA) vaccine candidate CV0501, to be given as a booster following the initial vaccine series.